TrialCancer2017

North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.

Robert R McWilliams et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.